SHANGHAI H&H MEDICAL TECHNOLOGY CO., LTD

H&H Medical is a high-tech enterprise specializing in the R&D, manufacturing, and commercialization of cardiovascular interventional medical devices, with its headquarters in Songjiang District, Shanghai. Driven by "Integration of Medical and Engineering Expertise" and "Independent R&D innovation", H&H Medical is dedicated to promoting the globalization of China's intelligent manufacturing of high-end medical devices.

The company holds industry-leading advantages in delivery systems, precision manufacturing, simulation modeling, and automated production. In the fields of transcatheter heart valve interventions, vascular interventions, drug delivery interventions, and smart interventional technologies, H&H Medical has commercialized multiple self-developed, world-leading products.

Founded by Ms. Lin Lin, a former cardiologist at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, has 20 years of clinical experience and R&D experience.

About Us

PROMOTE THE GLOBALIZATION OF CHINESE ORIGINAL MEDICAL DEVICES.

Product Center

K-Clip ®

Transcatheter Tricuspid Annuloplasty System

The world's first transcatheter tricuspid annuloplasty systemreplicates classic surgical procedures and repairs tricuspid regurgitation through minimally invasive surgery. It was approved for market by the National Medical Products Administration (NMPA) in March 2025. Key advantages include minimally invasive,repaid recovery, effective outcomes,user-friendly design and with an average operation time of just 30 minutes. 

K-Clip® fills a critical gap in China's interventional tricuspid valve field, becoming the first certified transcatheter solution for tricuspid regurgitation domestically. This pioneering device also ushers in a new era of Transcatheter Tricuspid Valve Annuloplasty (TTVA) globally, pioneering international research trends in tricuspid valve interventions. With over 250 patients successfully treated in China, K-Clip® has been granted access to the NMPA's priority review pathway for innovative medical devices.

K-Clip® has advanced global clinical validation through successful procedures in the U.S., Europe, and Asia-Pacific, earning recognition in leading cardiovascular journals.

▸  Obtained approval from the National Medical Products Administration (NMPA)

Vispearl ®

radiopaque embolic microspheres

PRODUCT CENTER

Developed with independent intellectual property rights, Vispearl® is a breakthrough radiopaque embolization microsphere platform capable of drug loading for tumor therapy. It is indicated for Transarterial Chemoembolization (TACE) in hepatocellular carcinoma (HCC) treatment.

Key Features

     • Smallest particle size of 40μm: Enables ultra-precise embolization and a stable release profile.

     • Radiopaque visibility under X-ray: Facilitates real-time imaging guidance, traceability, and                    synergistic integration with complementary HCC therapies, maximizing patient outcomes.

Clinical Development

Led by Professor Zhi-ping Yan, Director of the Department of Interventional Radiology at Zhongshan Hospital, Fudan University, and National Chairman of the Chinese Society of Interventional Radiology.

▸  Obtained approval from the National Medical Products Administration (NMPA)

C-Wave®

Vascular Catheter System

PRODUCT CENTER

Developed independently by Zhonghui Medical, a subsidiary of H&H Medical, the C-Wave® vascular catheter system is indicated for the treatment of intravascular calcified lesions and can be used either as a standalone therapy or in combination with stents.C-Wave® employs a breakthrough "adaptive shockwave technology" that follows the principle of “gentle on soft tissue, forceful on calcified structures”. This innovative mechanism enables targeted fracturing of calcium buildup from within the vessel wall while preserving surrounding soft tissues.

▸  Obtained approval from the National Medical Products Administration (NMPA)

SHARE OUR LATEST ACHIEVEMENTS WITH YOU

News Center